• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Cancer

NOVARTIS IMMUNO-ONCOLOGY DRUG CANDIDATE FAILS SKIN CANCER TRIAL

ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer. The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar…

Israeli scientist uses microbubbles to explode cancer cells

An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the future could perhaps also be used to treat diseases such as brain cancer, Alzheimer’s and Parkinson’s. The groundbreaking technique, developed by Tel Aviv University’s Tali Ilovitsh during her post-doctorate period…

Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead

Headed up by Scott Clarke, an ex-Roche exec who served as its global head of oncology partnering for Asia and emerging markets, the cancer immunotherapy company is working on several early assets, including TTX-030, a CD39-targeting antibody that last year attracted AbbVie’s interest and, according to preclinical data, seems to block an immune-inhibiting pathway in…

Imvax Inc. Raises $112 Million in Series C Financing

Imvax Inc. Raises $112 Million in Series C Financing Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme,  Phase 1 research into additional solid tumor indications and build out of the operational capabilities PHILADELPHIA, JULY 16, 2020 – Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being…